La cadena de opciones muestra datos clave de las opciones de acciones de Cutera a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cutera..

Cutera (OTC:CUTRQ) Bolsa, Cadena de Opciones

Cutera Inc is a medical device company that specializes in designing, developing, manufacturing, marketing, and servicing laser and other energy-based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States segment. Its products enable medical practitioners to perform safe procedures including treatment for acne, body contouring, skin resurfacing and revitalization, hair and tattoo removal, removal of benign pigmented lesions, and vascular conditions.

Cutera Inc

Barclays analyst Adrienne Yih maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Overweight and lowers the price target from $64 to $52.

News

Price Target

Analyst Ratings

ONON

Barclays Maintains Overweight on On Holding, Lowers Price Target to $52

Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.09 by 11.11 percent. This is a 20 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $7.74 million which missed the analyst consensus estimate of $25.32 million by 69.45 percent. This is a 40.47 percent decrease over sales of $12.99 million the same period last year.

Earnings

Earnings Misses

Lument Finance Trust Q1 Adj. EPS $0.08 Misses $0.09 Estimate, Sales $7.74M Miss $25.32M Estimate

ODDITY Tech Ltd. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) today announced the sale of 5,500,000 shares of its Class A ordinary shares by an entity affiliated with Oran Holtzman, ODDITY co-founder and CEO.
The transaction will enhance the free float and trading liquidity of ODDITY stock. Mr. Holtzman has no plan or intention to sell additional shares of the Company's stock, and he intends to preserve his control in the Company. As part of the transaction, Mr. Holtzman has entered into a lock-up agreement for a period of 1 year.
Following the transaction, Mr. Holtzman holds an approximately 23% ownership stake in the Company and controls a majority of the voting power. ODDITY has not received any proceeds from the transaction.
The transaction was effected pursuant to Rule 144 of the Securities Act of 1933. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Oddity Tech Announces Sale Of 5.5M Shares Of Its Class A Ordinary Shares by An Entity Affiliated With Oran Holtzman, Oddity Co-Founder And CEO

Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 28.95 percent decrease over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $868.00 thousand which beat the analyst consensus estimate of $575.80 thousand by 50.75 percent. This is a 40.00 percent increase over sales of $620.00 thousand the same period last year.

Earnings Beats

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Orchestra BioMed Hldgs Q1 EPS $(0.49) Misses $(0.48) Estimate, Sales $868.00K Beat $575.80K Estimate

MATW

Matthews International To Acquire The Dodge Company For $57M

AST SpaceMobile Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) reported first-quarter financial results after the market close on Monday. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/05/b45360483/ast-spacemobile-provides-business-update-and-first-quarter-2025-results">from the quarter</a>.
Q1 Earnings: AST SpaceMobile&nbsp;reported&nbsp;first-quarter revenue of $718,000, which may not compare to analyst <a href="http://benzinga.com/quote/asts/earnings">estimates</a>. The company reported a first-quarter adjusted loss of 20 cents per share, missing&nbsp;analyst estimates&nbsp;for a loss of 19 cents per share, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
AST SpaceMobile highlighted several achievements during the quarter, including &#8220;strong&#8221; progress on regulatory approvals and a multi-provider satellite orbital launch plan with five contracted launches over the next six to nine months. The company also said it advanced its SpaceMobile network commercialization efforts and has an expected revenue opportunity of&nbsp;$50 million&nbsp;to&nbsp;$75 million in the second half of 2025.
Total operating expenses came in at $63.7 million in the first quarter. The company ended the quarter with $874.5 million in cash, cash equivalents and restricted cash.
&#8220;AST SpaceMobile continues to execute on our bold strategy, progressing at an accelerated pace toward fulfilling our important mission of connecting the unconnected worldwide,&#8221; said&nbsp;Abel Avellan, founder, chairman and CEO of AST SpaceMobile.
&#8220;Today, we are at an inflection point for the company. We have ramped up manufacturing capacity and are now able to announce our plans to support five scheduled orbital launches over the next six to nine months. Commercially, we have also expanded our U.S. government opportunity and are in a position to start generating meaningful revenue during 2025.&#8221;
AST SpaceMobile executives will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET.
ASTS Price Action: <a href="http://benzinga.com/quote/asts" target="_blank" rel="noreferrer noopener">AST SpaceMobile shares</a> were up 1.80% in Monday&#8217;s after-hours session, trading at $27.65 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45327779/rocket-labs-new-defense-deal-2025-forecast-win-analyst-support">Rocket Lab&#8217;s New Defense Deal, 2025 Forecast Win Analyst Support</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/canyalcin">hakanyalicn</a>/Shutterstock.

SPACE

After-Hours Center

Movers

ASTS

AST SpaceMobile Reports Q1 Earnings: Key Highlights From The Quarter

Ark Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKR#NASDAQ">ARKR</a>) reported quarterly losses of $(2.57) per share. This is a 542.5 percent decrease over losses of $(0.40) per share from the same period last year. The company reported $39.73 million in sales this quarter. This is a 5.99 percent decrease over sales of $42.26 million the same period last year.

ARKR

Ark Restaurants Q2 EPS $(2.57) Down From $(0.40) YoY, Sales $39.73M Down From $42.26M YoY

<ul>
<li>Received overwhelming shareholder approval with 99.9% of votes cast in favor</li>
<li>Simplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments</li>
<li>Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten years</li>
<li>Royalty Pharma's diversified royalty portfolio to be combined with intellectual capital and investment platform of the Manager to advance shareholder value creation</li>
</ul>
&nbsp;Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma's 2025 Annual General Meeting and Special Meeting of Shareholders (the "Meeting"), marking a key milestone for the company.
"We are pleased to announce shareholder approval of our manager internalization, an important step that strengthens our corporate governance, enhances transparency, and further aligns our leadership team with shareholder interests," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "We are grateful for the strong support from our shareholders, and remain focused on delivering long-term value through our differentiated, innovation-focused business model."
With shareholder approval, Royalty Pharma will proceed with its transition from an external manager model to an integrated corporate structure, with the Royalty Pharma executive team and employees becoming direct employees of the company.
Key Benefits to Shareholders
The transaction is expected to result in multiple benefits for shareholders. On a financial basis, the acquisition is expected to reduce costs and enhance economic returns on investments. Specifically, the acquisition will generate cash savings of greater than $100 million in 2026 and greater than $175 million in 2030, and drive cumulative savings of greater than $1.6 billion over ten years. The acquisition also increases shareholder alignment, enhances corporate governance, ensures management continuity, maximizes employee retention as a result of the 5 to 9 year vesting of the shares received by management and simplifies Royalty Pharma's corporate structure. Lastly, internalizing the Manager has the potential to expand Royalty Pharma's&nbsp;shareholder base&nbsp;and further enhance the company's valuation over time.

RPRX

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition With 99.9% Votes Cast In Favor

General

ACHR

PLTR

Archer Says Has Forged A Partnership With Palantir To Build Artificial Intelligence For 'The Future Of Next-gen Aviation Technologies'

Montana Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRJ#NASDAQ">AIRJ</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $(0.06) by 533.33 percent. This is a 192.86 percent increase over losses of $(0.28) per share from the same period last year.

AIRJ

Montana Technologies Q1 EPS $0.26 Beats $(0.06) Estimate

Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) will report on Q1 2025.

Lument Finance Trust reported Q1 2025 Adj EPS $0.08

NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 47.62 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $13.38 million which beat the analyst consensus estimate of $4.26 million by 213.97 percent. This is a 869.91 percent increase over sales of $1.38 million the same period last year.

NuScale Power Q1 EPS $(0.11) Misses $(0.09) Estimate, Sales $13.38M Beat $4.26M Estimate

Dividends

MSIF

MSC Income Fund Announces Regular Quarterly Dividend Of $0.35/Shr And Supplemental Quarterly Dividend Of $0.01/Shr

Barclays analyst Adrienne Yih maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Equal-Weight and lowers the price target from $70 to $60.

Barclays Maintains Equal-Weight on Nike, Lowers Price Target to $60

MSC Income Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSIF#NYSE">MSIF</a>) reported quarterly earnings of $0.38 per share. This is a 5.56 percent increase over earnings of $0.36 per share from the same period last year. The company reported $33.23 million in sales this quarter. This is a 2.13 percent decrease over sales of $33.95 million the same period last year.

MSC Income Fund Q1 EPS $0.38 Up From $0.36 YoY, Sales $33.23M Down From $33.95M YoY

Archer Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) reported first-quarter financial results Monday after the bell. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/25/05/b45359248/archer-announces-first-quarter-results-highlighting-on-track-uae-launch-new-launch-edition-custome">company&#8217;s report</a>.
Q1 Earnings: Archer Aviation, which designs electric vertical take-off and landing (eVTOL) aircraft, reported a first-quarter loss of 17 cents per share, beating analyst <a href="http://benzinga.com/quote/achr/earnings">estimates</a> for a loss of 28 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Archer highlighted the announcement of its first two customers for its Midnight Edition launch in the first quarter and said it plans to deliver its first Midnight aircraft to the UAE in the coming months, with planned deployment slated for later this year.
The company also highlighted a partnership it signed with Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) in the first quarter to build AI for the future of next-generation aviation technologies. The companies plan to work together to develop AI software to improve a range of aviation systems.
Archer said its quarterly spending stayed within the previously guided range. The company ended the period with $1.03 billion in cash and cash equivalents, the highest cash position in company history. 
&#8220;Archer&#8217;s pushing the boundaries of what&#8217;s possible and reshaping the future of aviation for years to come.&nbsp;This quarter, the team made strong progress across our civil and defense efforts as we continue to deepen our strategic partner relationships and prepare for commercialization in the UAE later this year,&#8221; said&nbsp;Adam Goldstein, founder and CEO of Archer.
Archer reported an adjusted EBITDA loss of $109 million in the quarter and guided for a second-quarter adjusted EBITDA loss of $100 million to $120 million.
Archer Aviation executives will further discuss the quarter on a call with investors and analysts at 5 p.m. ET.
ACHR Price Action: <a href="http://benzinga.com/quote/achr" target="_blank" rel="noreferrer noopener">Archer Aviation shares</a> were up 5.29% in Monday&#8217;s after-hours session, trading at $9.56 at the time of publication, per <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45354683/tesla-probably-wont-make-money-on-ride-hailing-for-years-gary-black-says">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black</a></li>
</ul>
Photo: courtesy of Archer Aviation.

Guidance

Archer Aviation Reports Smaller-Than-Expected Loss In Q1, Company Says UAE Launch Remains 'On Track' For 2025, Shares Surge

Management

IFBD

Infobird Says On May 7 Xiangyang Wen Was Appointed As CEO

Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) affirms FY2025 Adj EPS guidance from $2.50-$2.80 to $2.50-$2.80 vs $2.65 analyst estimate. Affirms FY2025 sales outlook from $3.30 billion-$3.40 billion to $3.30 billion-$3.40 billion vs $3.34 billion estimate.

ACHC

Acadia Healthcare Co Affirms FY2025 Adj EPS Guidance of $2.50-$2.80 vs $2.65 Est; Affirms FY2025 Sales Guidance of $3.30B-$3.40B vs $3.34B Est

Barclays analyst Adrienne Yih maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Equal-Weight and lowers the price target from $309 to $276.

LULU

Barclays Maintains Equal-Weight on Lululemon Athletica, Lowers Price Target to $276

Star Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STHO#NASDAQ">STHO</a>) reported quarterly losses of $(0.57) per share. This is a 84.51 percent increase over losses of $(3.68) per share from the same period last year. The company reported $14.62 million in sales this quarter. This is a 42.51 percent decrease over sales of $25.44 million the same period last year.

Comments

Cutera

Cutera (CUTRQ) Opciones

Cutera (OTC:CUTRQ) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL